Journal Articles

Google hat Google Scholar
Bias Due to Correlation Between Times-at-Risk for Infection in Epidemiologic Studies Measuring Biological Interactions Between Sexually Transmitted Infections: A Case Study Using Human Papillomavirus Type Interactions Am J Epidemiol. 2016 15;184(12):873-883 Malagón T, Lemieux-Mellouki P, Laprise JF, Brisson M
Cost-effectiveness of the next generation nonavalent human papillomavirus vaccine in the context of primary human papillomavirus screening in Australia: a comparative modelling analysis Lancet Pub Health 2016;1(2):e66-75 Simms KT, Laprise JF, Smith MA, Lew JB, Caruana M, Brisson M, Canfell K
Population-Level Effects of Human Papillomavirus Vaccination Programs on Infections with Nonvaccine Genotypes. Emerg Infect Dis. 2016;22(10):1732-40. doi: 10.3201/eid2210.160675. Mesher D, Soldan K, Lehtinen M, Beddows S, Brisson M, Brotherton JM, Chow EP, Cummings T, Drolet M, Fairley CK, Garland SM, Kahn JA, Kavanagh K, Markowitz L, Pollock KG, Söderlund-Strand A, Sonnenberg P, Tabrizi SN, Tanton C, Unger E, Thomas SL
Effect of HPV on cervical cancer screening in Alberta. CMAJ. 2016;188(14):1035. Brisson M, Drolet M, Bénard É, Kreimer AR
Mathematical Modeling of the Transmission Dynamics of Clostridium difficile Infection and Colonization in Healthcare Settings: A Systematic Review. PLoS One. 2016;11(9):e0163880. doi: 10.1371/journal.pone.0163880. Gingras G, Guertin MH, Laprise JF, Drolet M, Brisson M
Comparison of 2-Dose and 3-Dose 9-Valent Human Papillomavirus Vaccine Schedules in the United States: A Cost-effectiveness Analysis. J Infect Dis. 2016 doi: 10.1093/infdis/jiw227 Laprise JF, Markowitz LE, Chesson HW, Drolet M, Brisson M
Can high overall human papillomavirus vaccination coverage hide sociodemographic inequalities? An ecological analysis in Canada Vaccine. 2016 doi: 10.1016/j.vaccine.2016.02.069. [Epub ahead of print] Drolet M, Deeks SL, Kliewer E, Musto G, Lambert P, Brisson M
Eurogin Roadmap 2015: How has HPV knowledge changed our practice: vaccines Int J Cancer. 2016 doi: 10.1002/ijc.30063 Brotherton JML, Jit M, Gravitt PE, Brisson M, Kreimer AR, Pai SI, Fakhry C, Monsonego J, Franceschi S
The Impact and Cost-Effectiveness of 3 doses of 9-Valent Human Papillomavirus (HPV) Vaccine among US Females Previously Vaccinated with 4-Valent HPV Vaccine J Infect Dis. 2016 doi: 10.1093/infdis/jiw046 [Epub ahead of print] HW Chesson, JF Laprise, M Brisson, LE Markowitz
Human Papillomavirus Vaccination at a Time of Changing Sexual Behavior Emerg Infect Dis. 2016;22(1):18-23. doi: 10.3201/eid2201.150791 Baussano I, Lazzarato F, Brisson M, Franceschi S
Assortative mixing as a source of bias in epidemiological studies of sexually transmitted infections: the case of smoking and human papillomavirus. Epidemiol Infect. 2015:1-10. [Epub ahead of print] Lemieux-Mellouki P, Drolet M, Brisson J, Franco EL, Boily MC, Baussano I, Brisson M
Health and Economic Impact of Switching from a 4-Valent to a 9-Valent HPV Vaccination Program in the United States JNCI J Natl Cancer Inst. 2016;108(1) doi: 10.1093/jnci/djv282 Brisson M, Laprise JF, Chesson HW, Drolet M, Malagón T, Boily MC, Markowitz LE
Fewer than three doses of HPV vaccine Lancet Oncol. 2015 DOI: http://dx.doi.org/10.1016/S1470-2045(15)00229-6 Jit M, Laprise JF, Choi YH, Brisson M
Prevalence and Frequency of Heterosexual Anal Intercourse Among Young People: A Systematic Review and Meta-analysis AIDS Behav. 2015 Jan 25. [Epub ahead of print] Owen BN, Brock PM, Butler AR, Pickles M, Brisson M, Baggaley RF, Boily MC
Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis The Lancet ID. 2015;15(5):565-80 Drolet M, Bénard É, Boily MC, Ali H, Baandrup L, Bauer h, Beddows S, Brisson J, Brotherton JML, Cummings T, Donovan B, Fairley CK, Flagg EW, Johnson AM, Kahn JA, Kavanagh K, Kjaer SK, Kliewer EV, Lemieux-Mellouki P, Markowitz L, Mboup A, Mesher D, Niccolai L, Oliphant J, Pollock KG, Soldan K, Sonnenberg P, Tabrizi SN, Tanton C, Brisson M
Comparison of two dose and three dose human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission model BMJ. 2015;350:g7584 Jit M, Brisson M, Laprise JF, Choi YH
Changing inequalities in cervical cancer: modeling the impact of vaccine uptake, vaccine herd effects, and cervical cancer screening in the post-vaccination era Cancer Epidemiol Biomarkers Prev. 2015 Jan;24(1):276-85 Malagón T, Drolet M, Boily MC, Laprise JF, Brisson M
Comparing the cost-effectiveness of two- and three-dose schedules of human papillomavirus vaccination: A transmission-dynamic modelling study Vaccine. 2014;32(44):5845–5853 Laprise JF, Drolet M, Boily MC, Jit M, Sauvageau C, Franco EL, Lemieux-Mellouki P, Malagón T, Brisson M
Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study Lancet Glob Health. 2014;2(7):e406-14 Jit M, Brisson M, Portnoy A, Hutubessy R
Two-dose strategies for human papillomavirus vaccination: How well do they need to protect? Vaccine. 2014 May 30;32(26):3237-42 Jit M, Choi YH, Laprise JF, Boily MC, Drolet M, Brisson M
Potential cost-effectiveness of the nonavalent human papillomavirus (HPV) vaccine Int J Cancer. 2014;134(9):2264-8 Drolet M, Laprise JF, Boily MC, Franco EL, Brisson M
Vaccinating Girls and Boys with Different Human Papillomavirus Vaccines: Can It Optimise Population-Level Effectiveness? PLoS One. 2013;8(6):e67072 Drolet M, Boily MC, Van de Velde N, Franco EL, Brisson M
Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: A transmission-dynamic modeling study Vaccine. 2013;31(37):3863-3871 Brisson M, Laprise JF, Drolet M, Van de Velde N, Franco EL, Kliewer EV, Ogilvie G, Deeks SL, Boily MC
Vaccinating Girls and Boys with Different Human Papillomavirus Vaccines: Can It Optimise Population-Level Effectiveness? PLOS One. 2013;8(6):e67072 Drolet M, Boily MC, Van de Velde N, Franco EL, Brisson M
Response to comment on Inequalities in Human Papillomavirus (HPV)-associated cancers: implications for the success of HPV vaccination. [J Natl Cancer Inst. 2013] J Natl Cancer Inst. 2013;105(10):750-1 Boily MC, Brisson M, Drolet M, Malagón T
Response to comment on Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis. [J Natl Cancer Inst. 2012] J Natl Cancer Inst. 2013;105(9):664-5 Brisson M, Drolet M, Boily MC, Malagón T, Franco EL, Laprise JF, Van de Velde N, Mayrand MH, Kliewer EV, Coutlée F
Sociodemographic Inequalities in Sexual Activity and Cervical Cancer Screening: Implications for the Success of Human Papillomavirus Vaccination Cancer Epidemiol Biomarkers Prev. 2013;22(4):641-52 Drolet M, Boily MC, Greenaway C, Deeks SL, Blanchette C, Laprise JF, Brisson M
The impact of differential uptake of HPV vaccine by sexual risks on health inequalities: A model-based analysis. Vaccine. 2013;31(13):1740-7 Malagón T, Joumier V, Boily MC, Van de Velde N, Drolet M, Brisson M.
Economic analyses to support decisions about HPV vaccination in low- and middle-income countries: a consensus report and guide for analysts. BMC Med. 2013;11(1):23 Jit M, Levin C, Brison M, Levin A, Resch S, Berkhof J, Kim J, Hutubessy R
Vaccination against herpes zoster in developed countries: State of the evidence. Hum Vaccin Immunother. 2013 Jan 16;9(5). [Epub ahead of print] Drolet M, Oxman MN, Levin MJ, Schmader KE, Johnson RW, Patrick D, Mansi JA, Brisson M
Inequalities in Human Papillomavirus (HPV)-Associated Cancers: Implications for the Success of HPV Vaccination J Natl Cancer Inst. 2013 Jan 7. [Epub ahead of print] Brisson M, Drolet M, Malagón T
Chapter 32: The Role of Mathematical Models in Vaccine Development and Public Health Decision Making Vaccinology: Principles and Practice, Chapter 32. John Wiley & Sons, 2012. Boily MC, Brisson M, Mâsse B, Anderson RM, Morrow WJW, Sheikh NA, Schmidt CS, Davies DH
Population-Level Impact of the Bivalent, Quadrivalent, and Nonavalent Human Papillomavirus Vaccines: A Model–Based Analysis J Natl Cancer Inst 2012 Oct 27 [Epub ahead of print] Van de Velde N, Boily MC, Drolet M, Franco EL, Mayrand MH, Kliewer EV, Coutlée F, Laprise JF, Malagón T, Brisson M
Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis Lancet Infect Dis. 2012;12(10):781-9 Malagón T, Drolet M, Boily MC, Franco EL, Jit M, Brisson J, Brisson M
Dynamic Transmission Modeling: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-5 Value Health 2012;15(6):828-34 Pitman R, Fisman D, Zaric GS, Postma M, Kretzschmar M, Edmunds J, Brisson M; ISPOR-SMDM Modeling Good Research Practices Task Force
Dynamic Transmission Modeling: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-5 Med Decis Making 2012;32(5):712-721 Pitman R, Fisman D, Zaric GS, Postma M, Kretzschmar M, Edmunds J, Brisson M; On Behalf of the ISPOR-SMDM Modeling Good Research Practices Task Force
Employment related productivity loss associated with herpes zoster and postherpetic neuralgia: A 6-month prospective study Vaccine 2012; 30:2047-50 Drolet M, Levin MJ, Schmader KE, Johnson R, Oxman MN, Patrick D, Fournier SO, Mansi JA, Brisson M*
The psychosocial impact of an abnormal cervical smear result: a prospective and comparative study Psychooncology 2012;21(10):1071-81 Drolet M, Brisson M*, Maunsell E, Franco EL, Coutlée F, Ferenczy A, Ratnam S, Fisher W, Mansi JA
The impact of anogenital warts on health-related quality of life: a 6-month prospective study Sex Transm Dis 2011; 38:949-56 Drolet M, Brisson M*, Maunsell E, Franco EL, Coutlée F, Ferenczy A, Ratnam S, Fisher W, Mansi JA
Association between prodromal pain and the severity of acute herpes zoster and utilization of health care resources Eur J Pain 2011;15:1100-6 Benbernou A, Drolet M, Levin MJ, Schmader KE, Oxman MN, Johnson R, Patrick D, Camden S, Mansi JA, Brisson M*
Incremental impact of adding boys to current HPV vaccination programmes: Role of herd immunity J Infect Dis 2011; 204:372-6 Brisson M*, Van de Velde N, Franco EL, Drolet M, Boily MC
Accounting for methodological, model and parametric uncertainty in decision analytic models: a practical guide Med Decis Making 2011;31:675-92 Bilcke J, Beutels P, Brisson M, Jit M
Modelling the Epidemiology of Infectious Diseases for Decision Analysis: A Primer PharmacoEconomics 2011;29:371-86 Jit M, Brisson M
Quality of Life Loss to Genital Warts: Baseline Analyses from a Prospective Cohort Study Sex Transm Infect 2011;87:209-15 Sénécal M, Brisson M*, Maunsell E, Ferenczy A, Franco EL, Ratnam S, Coutlée F, Palefsky JM, Mansi JA
Different population-level vaccination effectiveness for HPV-types 16, 18, 6 and 11 Sex Transm Infect 2011; 87:41-3 Brisson M*, Van de Velde N, Boily MC
The impact of herpes zoster and postherpetic neuralgia on quality-of-life CMAJ 2010;182:1731-6 Drolet M, Brisson M*, Levin M, Schmader K, Oxman M, Johnson R, Camden S, Mansi JA
A prospective study of the herpes zoster severity of illness Clin J Pain 2010;26:656-66 Drolet M, Brisson M*, Levin M, Schmader K, Oxman M, Johnson R, Camden S, Mansi JA
Understanding Differences in Predictions of HPV Vaccine Effectiveness: A Comparative Model-Based Analysis Vaccine 2010;28:5473–5484 Van de Velde N, Brisson M*, Boily MC
Prevention strategies for herpes zoster and post-herpetic neuralgia J Clin Virol 2010;48 Suppl 1:S14-9 Levin M, Gershon A, RH Dworkin, Brisson M, Stanberry L
Proceedings of the Modeling Evidence in HPV Pre-Conference Workshop Malmo, Sweden (May 9-10. 2009) Clin Ther 2010;32:1-19 Craig BM, Brisson M, Chesson H, Giuliano AR, Jit M
Predictors of postherpetic neuralgia among patients with herpes zoster: a prospective study Journal of Pain 2010 Apr 29 [Epub ahead ofprint] Drolet M, Brisson M*, Levin M, Schmader K, Oxman M, Johnson R, Camden S, Mansi JA
The Manitoba Human Papillomavirus Vaccine Surveillance and Evaluation Syste. Health Reports 2010;21:1-8 Kliewer EV, Demers AA, Brisson M, Severini A, Lotocki R, Elias B, Hammond G, Wurtak G, the Manitoba HPV Research Group
Modeling the Impact of One- and Two-Dose Varicella Vaccination on the Epidemiology of Varicella and Zoster Vaccine 2010;28:3385-97 Brisson M*, Melkonyan G, Drolet M, De Serres G, Thibeault R, De Wals P
Health-Related Quality of Life Lost to Rotavirus-Associated Gastroenteritis in Children and their Parents: A Canadian Prospective Study Pediatr Infect Dis J 2010;29:73-75 Brisson M*, Sénécal M, Drolet M, Mansi JA
Economic Evaluation of Human Papillomavirus Vaccination in Developed Countries Public Health Genomics 2009;12:343-51 Brisson M*, Van de Velde N, Boily MC
Prevalence and type distribution of human papillomavirus in 5000 British Columbia women – Implications for vaccination Cancer Causes Control 2009;20:1387-96 Moore R, Ogilvie G, Fornika D, Moravan V, Amirabbasi-Beik M, Kollar A, Burgess T, Hsu T, Towers L, Lo J, Brisson M, Matisic J, Brooks-Wilson A
Twenty Year Trends in the Incidence and Prevalence of Diagnosed Anogenital Warts in Canada Sex Transm Dis 2009; 36:380-6 Kliewer EV, Demers AA, Elliott L, Lotocki R, Butler JRG, Brisson M
Measuring the Impact of Rotavirus Acute Gastroenteritis Episodes (MIRAGE): A prospective community-based study Can J Infect Dis Med Microbiol 2008;19:397-404 Sénécal M, Brisson M*, Lebel MH, Yaremko J, Wong R, Gallant LA, Garfield H, Ableman DJ, Ward RL, Sampalis J and Mansi JA for the MIRAGE study group
Chapter 7: Modeling cervical cancer prevention in developed countries Vaccine 2008; Suppl 10:K76-86 Kim JJ, Brisson M, Edmunds J, Garnett G, Goldie SJ
Estimating the Number Needed to Vaccinate to Prevent Herpes Zoster Related Disease, Health Care Resource Use and Mortality Can J Public Health 2008; 99:383-6 Brisson M*
Potential Cost-effectiveness of vaccination against Herpes Zoster and PHN in Canada Hum Vaccine 2008; 4: 238-245 Brisson M*, Pellissier JM, Quach C, De Wals P
Cost-Effectiveness of a Herpes Zoster vaccine: flawed assumptions regarding efficacy against PHN Clin Infect Dis 2007; 45:1527-9 Brisson M*, Pellissier JM, Levin MJ
Estimating the Number Needed to Vaccinate to Prevent HPV related disease and Mortality CMAJ 2007;177:464-8 Brisson M*, Van de Velde N, Boily MC, De Wals P
The Potential Cost-Effectiveness of Prophylactic Human Papillomavirus Vaccines in Canada Vaccine 2007; 25:5399-408 Brisson M*, Van de Velde N, Boily MC, De Wals P
Modelling Human Papillomavirus Vaccine Effectiveness: Quantifying the Impact of Parameter Uncertainty Am J Epidemiol 2007; 165:762-75 Van de Velde N, Brisson M*, Boily MC
Impact of Model, Methodological and Parameter Uncertainty in the Economic Evaluation of Vaccination Programs Med Decis Making 2006; 26: 434-446 Brisson M, Edmunds WJ
A Cost-Utility Analysis of Losartan versus Atenolol in the Treatment of Hypertension with Left Ventricular Hypertrophy Pharmacoeconomics 2006;24:387-400 Anis AH, Sun H, Singh S, Woolcott J, Nosyk B, Brisson M
Modelling the impact of vaccination on the epidemiology of varicella zoster virus in Australia Aust N Z J Public Health 2005;29:544-51 Gidding HF, Brisson M, Macintyre CR, Burgess MA
Persistence with Antihypertensive Therapy in Newly Diagnosed Patients: A Population-Based Study J Hum Hypertens 2005; 19:607-13 Bourgault C, Sénécal M, Brisson M, Marentette M, Grégoire JP
A Cost-utility Analysis of Finasteride in the Treatment of Benign Prostatic Hyperplasia Can J Urol 2004; 11; 2327-39 McDonald H, Hux M, Brisson M, Bernard L, Nickel CJ
Varicella Vaccination in England and Wales: Cost-utility analysis Arch Dis Child 2003; 88:862-9 Brisson M, Edmunds WJ
Economic evaluation of vaccination programmes: The impact of herd-immunity Med Decis Making 2003; 23:76-82 Brisson M*, Edmunds WJ
Varicella vaccination: Impact of vaccine efficacy on the epidemiology of VZV J Med Virol 2003; 70 Suppl 1:S31-7 Brisson M*, Edmunds WJ, Gay NJ
Epidemiology of Varicella-Zoster virus in England and Wales J Med Virol 2003; 70 Suppl 1:S9-14 Brisson M*, Edmunds WJ
The effect of vaccination on the epidemiology of varicella zoster virus Journal of Infection 2002; 44: 211-219 Edmunds WJ, Brisson M
Varicella vaccination: a double-edged sword? Commun Dis Public Health 2002; 5:185-186 Edmunds WJ, Brisson M, Gay NJ, Miller E
Exposure to Varicella Boosts Immunity to Herpes-zoster: Implications for mass vaccination against chickenpox Vaccine 2002; 20: 2500-2507 Brisson M*, Gay NJ, Edmunds WJ, Andrews NJ
Deaths from chickenpox in adults are decreasing BMJ 2002; 324:609 Brisson M*, Edmunds WJ, Gay NJ, Miller E
Varicella Vaccine and Shingles JAMA 2002; 287:2211-2 Brisson M*, Edmunds WJ, Gay NJ, Miller E
Deaths from pertussis are underestimated in England Arch Dis Child 2002; 86:336-8 Crowcroft NS, Andrews N, Rooney C, Brisson M, Miller E
The potential cost-effectiveness of acellular pertussis booster vaccination in England and Wales Vaccine 2002; 20:1316-1330 Edmunds WJ, Brisson M, Melegaro A
The cost-effectiveness of varicella vaccination in Canada Vaccine 2002; 20: 1113-1125 Brisson M*, Edmunds WJ
Epidemiology of varicella and zoster in Canada and the United-Kingdom Epidemiol Infect 2001; 127:305-314 Brisson M*, Edmunds WJ, Law B, et al
The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales Vaccine 2001;19:3076-90 Edmunds WJ, Brisson M, Rose JD
Modelling the impact of immunisation on the epidemiology of varicella zoster virus Epidemiol Infect 2000; 125:651-669 Brisson M*, Edmunds WJ, Gay NJ, Law B, De Serres G
Epidemiology of invasive and other pneumococcol disease in children in England and Wales 1996-1998 Acta Pediatr 2000; Suppl 89: 11-16 Miller E, Waight P, Efstratiou A, Brisson M, Johnson A, George R
Analysis of varicella vaccine breakthrough rates: Implications for the effectiveness of immunisation programs Vaccine 2000;18:2775-2778 Brisson M*, Edmunds WJ, Gay NJ, Law B, De Serres G
Highlights of the sexual activity of the heterosexual population in the province of Quebec Sex Transm Inf 1999;75:296-299 Brisson M, Boily MC, Mâsse BR, Adrien A, Leaune V

*corresponding author

Login

Admin panel